Published: August 03, 2011
Mayo Clinic Finds New Bacterium Causing Tick-Borne Illness Ehrlichiosis in Wis., Minn.
ROCHESTER, Minn. - (BUSINESS WIRE) - A new tick-borne bacterium infecting humans with ehrlichiosis has
been discovered in Wisconsin and Minnesota. It was identified as a new
strain of bacteria through DNA testing conducted at Mayo Clinic. The
findings appear in the Aug. 4 edition of the New England Journal of
Medicine.
TELECONFERENCE BRIEFING: Dr. Bobbi Pritt and Carol Werner, will
discuss the discovery and answer questions during a teleconference
briefing Tuesday, Aug. 2, at 1:30 p.m. CST. To receive call-in
information for this briefing, please call 507-284-5005 or e-mail newsbureau@mayo.edu.
VIDEO ALERT: Interviews with researchers, b-roll of ticks and a
photos of the bacterium and a tick are available at Mayo
Clinic News Blog.
Doctors at Mayo Clinic, the Centers for Disease Control and Prevention
(CDC), the University of Minnesota, the University of Wisconsin, and
state and local health departments say the new species from the Ehrlichia
genus can cause a feverish
illness in humans. The new bacterium, not yet named, has been
identified in more than 25 people and found in black-legged ticks, also
known as deer ticks (Ixodes scapularis), in Minnesota and
Wisconsin. Researchers used culture and genetic analyses.
"Before this report, human ehrlichiosis was thought to be very
rare or absent in Minnesota and Wisconsin," says Bobbi Pritt, M.D., a
Mayo Clinic microbiologist and director of the Clinical Parasitology and
Virology Laboratories who helped coordinate the multi-agency team.
"Therefore, physicians might not know to look for Ehrlichia infections
at all."
Ehrlichia infect and kill white blood cells and may cause fever,
body aches, headache and fatigue. More severe disease may involve
multiple organs such as the lungs, kidneys and brain and require
hospitalization. Ehrliochosis
rarely results in death.
All four patients described in the New England Journal of Medicine article
suffered fever and fatigue. One patient, who had already received a
bilateral lung transplant, was hospitalized briefly for his illness. All
four patients recovered following antibiotic treatment with doxycycline,
the drug of choice for treating ehrlichiosis. Although more than
25 cases have been identified, many more have likely been missed or
unreported, Dr. Pritt says.
The investigation began after Carol Werner, then a technologist at Mayo
Clinic Health System's Eau Claire hospital, noted an abnormal Ehrlichia
Polymerace Chain Reaction (PCR) result in 2009 and raised the first
red flag. Mayo Clinic then began investigating with the CDC, the
universities and several public health departments. The Minnesota
Department of Health last year put out a health advisory alerting people
that it and its Wisconsin counterpart were seeing increasing reports of ehrlichiosis
in humans.
"As the deer tick population continues to spread and increase across
Wisconsin, we are likely to see increasing incidence of this new
infection, just as we have seen with Lyme disease and anaplasmosis which
are transmitted by the same tick species,'' says co-author Susan
Paskewitz, Ph.D, an entomologist at the University of Wisconsin-Madison.
To date, thousands of blood samples from across the United States have
been screened by Mayo Clinic laboratory technologists, and the bacterium
has been detected only in specimens collected from Wisconsin and
Minnesota. Thousands of ticks across the country have also been
analyzed, and only those from the two states have been carriers.
Because the bacterium is likely transmitted through the bite of an
infected tick, Dr. Pritt cautions that people should apply insect
repellent and wear pants and long-sleeved shirts when active outdoors.
Doctors need to know to test for ehrlichiosis in the two states
so the diagnosis is not missed. However, traditional blood antibody
tests may offer misleading results and fail to accurately identify the
new species. A specific antibody test for the new bacterium has
been developed by the CDC but isn't widely available. Instead, a
molecular blood test that detects DNA from the new Ehrlichia species
is the preferred method for detecting this disease in symptomatic
patients.
When testing for this new Ehrlichia species, physicians should
also consider testing for other tick-borne diseases, such as Lyme
disease, babesiosis and anaplasmosis, all prevalent in Minnesota and
Wisconsin, Dr. Pritt says.
Genetically, the new bacterium bears closest similarity to another
species of Ehrlichia - E. muris - that infects small
rodents and deer in Eastern Europe and Asia. E. muris rarely infects
humans, and no cases have been reported in North America.
Other authors include Lynne M. Sloan; Matthew Binnicker, Ph.D.; Scott
Cunningham; Mark Wilhelm, M.D.; and Robin Patel, M.D., all of Mayo
Clinic; Ulrike Munderloh, Ph.D., and Curtis M. Nelson, both of the
University of Minnesota; David Neitzel and Gongping Liu, Ph.D., both of
the Minnesota Department of Health; Diep Hoang Johnson; Jevon McFadden,
M.D.; Christopher Steward; and Jeffrey Davis, M.D., all of the Wisconsin
Division of Public Health; Joni Franson; Scott Martin, M.D.; and Vipul
Trivedi, M.D., all of Mayo Clinic Health System in Eau Claire; Kay
Bogumill, R.N., of the Eau Claire County Health Department; Mary
Bjorgaard, R.N., of the Burnett County (Wis.) Department of Health and
Human Services; David Warshauer, Ph.D., of the Wisconsin State
Laboratory of Hygiene; Kristina McElroy, D.V.M.; William Nicholson,
Ph.D.; Jennifer McQuiston, D.V.M.; and Marina Eremeeva, M.D., Ph.D.,
Sc.D., all of the Centers for Disease Control and Prevention.
About Mayo Clinic
Mayo
Clinic is a nonprofit worldwide leader in medical care, research and
education for people from all walks of life. For more information, visit http://mayoclinic.org/about
and www.mayoclinic.org/news.

Mayo Clinic
Robert Nellis
507-284-5005 (days)
507-284-2511
(evenings)
newsbureau@mayo.edu
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News